ALISO VIEJO, Calif. – July 31, 2023 – MicroVention, Inc. today celebrated the one-year anniversary of the FRED™ X Flow Diverter, marking over 1,000 patients treated across the United States since its launch.
The FRED X Flow Diverter builds on the established FRED platform with the addition of X Technology, a surface modification designed to reduce material thrombogenicity while maintaining the device's proven flow diversion performance for the treatment of intracranial aneurysms.
"Reaching over 1,000 patients treated in just one year is a testament to physician confidence in the FRED X Flow Diverter," said a MicroVention representative. "We are proud of the impact this technology has had on patient care and look forward to continuing to support physicians treating complex aneurysms."
The FRED X Flow Diverter continues to expand physician access to advanced flow diversion technology for the treatment of intracranial aneurysms across the U.S.
About MicroVention
MicroVention, Inc. is committed to advancing the treatment of complex diseases within the neurovascular market by providing innovative technologies and evidence-driven education for physicians dedicated to improving patient care. As a wholly owned subsidiary of Terumo Corporation, MicroVention develops, manufactures and markets innovative neuro-interventional products and services for the diagnosis and treatment of neurovascular diseases and adjacent markets.
